Detected ·
Allyx Therapeutics
$26.5M—
Allyx Therapeutics, a Yale University spinout focused on Alzheimer's research, closed a $26.5M financing round, bringing total funding to over $60M. The company is preparing to launch a pivotal Phase 2 clinical trial of its lead therapy, ALX-001.
- Website
- allyxthera.com
- Amount
- $26 500 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-25 00:04:49 UTC
- Signal ID
- f96643f4-dcb5-4296-a858-fc691cb558de
As the API returns it
{
"id": "f96643f4-dcb5-4296-a858-fc691cb558de",
"created_at": "2026-07-25T00:04:49.089866Z",
"company_name": "Allyx Therapeutics",
"company_website_url": "allyxthera.com",
"company_linkedin_url": "https://www.linkedin.com/company/allyx-therapeutics",
"event_type": "funding",
"funding_amount": 26500000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Allyx Therapeutics, a Yale University spinout focused on Alzheimer's research, closed a $26.5M financing round, bringing total funding to over $60M. The company is preparing to launch a pivotal Phase 2 clinical trial of its lead therapy, ALX-001.*"
}